Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Johan F. Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, Tommaso De Pas, Marcin Zielinski, Moon Soo Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Haruhiku Nakayama, Libor Havel, Haruhiko Kondo, Tetsuya Mitsudomi, Konstantinos Zarogoulidis, Oleg A. Gladkov, Katalin Udud, Hirohito Tada, Hans Hoffman, Anders Bugge, Paul TaylorEmilio Esteban Gonzalez, Mei Lin Liao, Jianxing He, Jean Louis Pujol, Jamila Louahed, Muriel Debois, Vincent Brichard, Channa Debruyne, Patrick Therasse, Nasser Altorki

Research output: Contribution to journalArticlepeer-review

227 Citations (Scopus)

Fingerprint Dive into the research topics of 'Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences